Cyclacel Limited (Dundee, UK) uses cell cycle control biology and state-of-the-art rational drug design chemistry to develop novel cancer therapeutics including small molecule CDK inhibitors (CYC200; CYC400), Penetratin®-small molecule complexes (CYC300), Pimetic™ small molecules mimicking natural cancer suppressing genes (CYC100), and intelligent delivery and targeting systems (Penetratin® and SGC™ technologies). Cyclacel’s Polgen division (Cambridge, UK) is in a world-first effort to validate, develop assays and discover drugs arising from 100 genomic targets regulating cancer mitosis. CYC202, the lead drug candidate is entering Phase I this autumn as the 3rd entry in a worldwide race involving several pharmaceutical majors.
Cyclacel’s clinical strategy for CYC202 includes several Phase I and Phase II trials in patients with solid tumors with the objective of defining the most attractive population to test the drug’s properties, as well as studying pharmacokinetics and optimal dosing. The commercialization strategy calls for positioning the company’s CDK inhibitors as modern, mechanism-based medicines with low toxicity and high target specificity to be used for treating cancer as a chronic disease. CDK inhibitors in general, and CYC202 in particular, have shown activity in animal models of non-cancerous hyperproliferative diseases such as autoimmune, cardiovascular, dermatological and inflammatory conditions.
| Contact Details: |
| James Lindsay Place; Dundee Technopole |
| Dundee |
| Tayside |
| DD1 5JJ |
| United Kingdom |
| Tel: | 44 1382 206 062 |
| Fax: | 44 1382 206 067 |
| Email: | srombotis@cyclacel.com |
| WWW: | www.cyclacel.com/
|
|
Loading...
|
Recent Publications by Cyclacel Limited: |  |
Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents.
PURPOSE: The aims of this study were to investigate whether the... | 1st August, 2008
| Cyclacel
| Clin Cancer Res. 2008 Jul 1;14(13):4326-35.
DOI Direct Link |
Characterisation of the Bax-nucleophosmin interaction: the importance of the Bax C-terminus.
The molecular chaperone nucleophosmin has been identified as a novel Bax... | 17th July, 2008
| Astellas CNS Research in Edinburgh, The University of Edinburgh, The
| Apoptosis. 2008 Mar;13(3):394-403.
DOI Direct Link |
Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor seliciclib (R-roscovitine) in vitro and in vivo.
Seliciclib (R-roscovitine, CYC202) is a small molecule inhibitor of... | 7th May, 2008
| Cyclacel Ltd, James Lindsay Place, Dundee DD1 5JJ, UK.
| Drug Metab Dispos. 2008 Mar;36(3):561-70. Epub 2007 Nov 29.
DOI Direct Link |
REPLACE: a strategy for iterative design of cyclin-binding groove inhibitors.
We describe a drug-design strategy termed REPLACE (REplacement with... | 7th April, 2007
| Cyclacel Limited, James Lindsay Place, Dundee, DD1 5JJ, UK.
| Chembiochem. 2006 Dec;7(12):1909-15.
DOI Direct Link |
Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance.
Polo-like kinases (Plks) have several functions in mitotic progression and... | 4th January, 2007
| Cyclacel Ltd., James Lindsay Place, Dundee DD1 5JJ, UK.
| Nat Chem Biol. 2006 Nov;2(11):608-17. Epub 2006 Oct 8.
DOI Direct Link |
→View more Cyclacel Limited research publications. |
Press Releases on Cyclacel Limited:
|
 |
| Cyclacel to present at BIO CEO & Investor Conference |
1st February, 2004 |
Cyclacel |
Cyclacel
to present at BIO CEO & Investor Conference
Dundee, UK, 18 February 2004 - Cyclacel Limited, the UK-based biopharmaceutical company, announced today that it will be presenting in
|
| CYCLACEL COMPLETES $39 MILLION PRIVATE PLACEMENT |
1st January, 2004 |
Cyclacel |
CYCLACEL COMPLETES $39 MILLION PRIVATE PLACEMENT
Funds to Support Growing Clinical Pipeline and Preclinical Programs; Total Raised To Date Exceeds $100 Million
Dundee, UK, 29 January 2004 -
|
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 12 individuals from Cyclacel Limited using this service.
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 638 times since April 2007, the link to the organisation's website has been followed 99 times
Recent Search Terms used to find this page: cyclacel dundee | cyclacel dundee | cyclacel uk | cyclacel limited cambridge | cyclacel limited | Polgen division of Cyclacel Ltd Cambridge | cyclacel antibodies | cyclacel uk | Cyclacel Limited | cyclacel limi | .
Search for more companies in Dundee
Search for more companies in Tayside
This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for
Cyclacel Limited
